| Literature DB >> 21458181 |
Valentina Ambrosini1, Silvia Nicolini, Paola Caroli, Cristina Nanni, Arianna Massaro, Maria Cristina Marzola, Domenico Rubello, Stefano Fanti.
Abstract
Lung cancer (LC) still represents one of the most common tumours in both women and men. PET/CT is a whole-body non-invasive imaging procedure that has been increasingly used for the assessment of LC patients. In particular, PET/CT added value to CT is mainly related to a more accurate staging of nodal and metastatic sites and to the evaluation of the response to therapy. Although the most common PET tracer for LC evaluation is 18F-FDG, new tracers have been proposed for the evaluation of lung neuroendocrine tumours (68Ga-DOTA-peptides, 18F-DOPA) and for the assessment of central nervous system metastasis (11C-methionine). This review focuses on the main clinical applications and accuracy of PET/CT for the detection of non-small cells lung cancer (NSCLC), broncho-alveolar carcinoma (BAC), small cells lung cancer (SCLC), lung neuroendocrine tumours (NET) and solitary pulmonary nodules (SPN).Entities:
Mesh：
Year: 2011 PMID： 21458181 DOI： 10.1016/j.ejrad.2011.03.020
Source DB: PubMed Journal: Eur J Radiol ISSN： 0720-048X Impact factor: 3.528